Durect CORP Form 4 insider transactions

DURECT Corp's President and CEO, James E. Brown, reported the cancellation of 103,077 stock options as part of the Bausch Health merger agreement.

A DURECT Corporation director reported changes in beneficial ownership following the company's merger with a Bausch Health Americas subsidiary.

DURECT Corporation's President and CEO, James E. Brown, reported the disposition of all his beneficial ownership in common stock and derivative securities following the company's merger with Bausch Health Americas, Inc.

DURECT Corporation's Director, Gail J. Maderis, reported the disposition of all her common stock and the cancellation of stock options following the company's merger with Bausch Health Americas, Inc.

DURECT's Chief Medical Officer, Norman Sussman, disposed of all common stock and certain stock options following the company's acquisition by Bausch Health Americas, Inc.

DURECT Corporation has been acquired by Bausch Health Americas, Inc. through a tender offer and subsequent merger, with shareholders receiving $1.75 per share cash and a contingent value right.

DURECT Corporation's Director, Peter S. Garcia, reported the disposition of common stock and stock options following the company's merger with Bausch Health Americas, Inc.

DURECT Director Mohammad Azab disposed of common stock and stock options as part of the company's merger with Bausch Health Americas, Inc. for $1.75 cash per share plus contingent value rights.

DURECT Corporation's Chief Financial Officer, Timothy M. Papp, reported the disposition of all beneficial ownership in common stock and cancellation of stock options following the company's acquisition by Bausch Health Americas, Inc.

DURECT Corporation Director Gail M. Farfel exercised 5,500 stock options at $1.22 per share, increasing her direct beneficial ownership as part of a pre-planned transaction.

DURECT Corporation's President and CEO, James E. Brown, exercised a significant number of stock options, acquiring 261,923 shares of common stock.

DURECT Corporation Director Judith J. Robertson acquired 5,500 shares of common stock through option exercise at $1.22 per share.

DURECT Corp. Director Peter S. Garcia exercised options to acquire 5,500 shares of common stock at $1.22 per share.

DURECT Corporation Director Gail J. Maderis acquired 5,500 shares of common stock through the exercise of stock options at $1.22 per share.

DURECT Corporation's President and CEO, James E. Brown, exercised options to acquire 10,000 shares of common stock at $1.30 per share, effective September 8, 2025.

DURECT Corporation's Chief Financial Officer, Timothy M. Papp, acquired 110,000 shares of common stock through the exercise of stock options at $1.30 per share.

DURECT Corp. Director R. Scott Asen increased his beneficial ownership by purchasing 5,917 shares of common stock.

DURECT Corp Director R. Scott Asen increased his beneficial ownership through recent common stock purchases totaling over 200,000 shares.

DURECT Corporation's President and CEO, James E. Brown, was granted 96,959 shares of common stock through a restricted stock unit award, vesting on July 11, 2025.

DURECT Corporation's Chief Medical Officer, Norman Sussman, was granted 46,425 shares of common stock through a restricted stock unit award, vesting in one year.

DURECT Corporation's Chief Financial Officer, Timothy M. Papp, was granted 46,659 shares of common stock in the form of restricted stock units, vesting on July 11, 2026.

DURECT Corporation's Chief Medical Officer, Norman Sussman, acquired 104,000 stock options on October 14, 2024, according to a Form 4 filing with the SEC.

Timothy M. Papp, CFO of DURECT Corporation, reports the acquisition of 110,000 stock options.

DURECT Corporation's CEO, James E. Brown, was granted 375,000 stock options on October 14, 2024, according to a Form 4 filing with the SEC.

Director Judith J. Robertson acquired stock options in DURECT Corporation on September 25, 2024.

Director Gail J. Maderis acquired 5,500 stock options in DURECT Corporation on September 25, 2024, at an exercise price of $1.22.

Director Peter S. Garcia acquired 5,500 stock options in DURECT Corporation on September 25, 2024.

Director Gail M. Farfel acquired 5,500 stock options in DURECT Corporation on September 25, 2024.

Director Terrence F. Blaschke acquired 5,500 stock options in DURECT Corporation on September 25, 2024, according to a Form 4 filing.

Director Mohammad Azab acquired 5,500 stock options in DURECT Corporation on September 25, 2024, exercisable at $1.22.